Related references
Note: Only part of the references are listed.Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents
Iuliana Vaxman et al.
BONE MARROW TRANSPLANTATION (2021)
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients
Benjamin A. Derman et al.
JOURNAL OF GERIATRIC ONCOLOGY (2021)
Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions
Nitya Nathwani et al.
JCO ONCOLOGY PRACTICE (2020)
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action
Kitsada Wudhikarn et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos et al.
LANCET (2020)
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees et al.
BLOOD (2020)
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
Brian G. M. Durie et al.
BLOOD CANCER JOURNAL (2020)
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jagoda K. Jasielec et al.
BLOOD (2020)
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo et al.
LANCET HAEMATOLOGY (2020)
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma
Pashna N. Munshi et al.
CANCER (2020)
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
Murielle Roussel et al.
Lancet Haematology (2020)
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
Saad Z Usmani et al.
Lancet Haematology (2020)
Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
Francesca Gay et al.
BLOOD (2020)
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Jonathan L. Kaufman et al.
BLOOD (2020)
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Thierry Facon et al.
BLOOD (2019)
Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
Shalin Kothari et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
Elizabeth K. O'Donnell et al.
BLOOD (2019)
Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study
Claudia A. M. Stege et al.
BLOOD (2019)
Geriatric Assessment in Older Adults with Multiple Myeloma
Tanya M. Wildes et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2019)
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos et al.
LANCET (2019)
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H. Jackson et al.
LANCET ONCOLOGY (2019)
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Sarah A. Holstein et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial
H. Goldschmidt et al.
LEUKEMIA (2018)
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
Elizabeth K. O'Donnell et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016
Andrew J. Cowan et al.
JAMA ONCOLOGY (2018)
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction A Systematic Review and Meta-analysis
Binod Dhakal et al.
JAMA ONCOLOGY (2018)
Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study
Claudia A. M. Stege et al.
BLOOD (2018)
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)
Francesca Gay et al.
BLOOD (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon et al.
BLOOD (2018)
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
P. Musto et al.
ANNALS OF ONCOLOGY (2017)
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L. McCarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
Sarah A. Holstein et al.
LANCET HAEMATOLOGY (2017)
Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States
Luciano J. Costa et al.
BLOOD ADVANCES (2017)
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
H. Jiang et al.
LEUKEMIA (2016)
Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis
Emma C. Scott et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
Sonja Zweegman et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma
A. Keith Stewart et al.
BLOOD (2015)
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay et al.
LANCET ONCOLOGY (2015)
Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation
Manish Sharma et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert et al.
CLINICAL CANCER RESEARCH (2014)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
A. K. Nooka et al.
LEUKEMIA (2014)
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Lotfi Benboubker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
A. Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M. Collins et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
Gareth J. Morgan et al.
BLOOD (2012)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis
P. Kapoor et al.
LEUKEMIA (2011)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
John Koreth et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
